Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.
De Campos, E S
Bell, D R
Steward, William P
Vansteenkiste, J F
Ewers, S B
AffiliationCRC Department of Oncology, Christie Hospital NHS Trust, Manchester, UK.
MetadataShow full item record
AbstractAnaemia commonly occurs in cancer patients receiving chemotherapy, often necessitating blood transfusion. This multicentre study was designed to evaluate the efficacy and safety of epoetin alpha in preventing the decline in haemoglobin (Hb) level, and to determine whether the transfusion requirement could be reduced, in patients receiving 4-6 cycles of primarily platinum-based combination cyclic chemotherapy for small cell lung cancer (SCLC). A total of 130 non-anaemic SCLC patients were randomized to receive no additional treatment (n = 44), epoetin alpha 150 IU kg(-1) subcutaneously (s.c.) three times a week (n = 42) or 300 IU kg(-1) s.c. three times a week (n = 44). Reductions in epoetin alpha dosage were made during the study if Hb level increased to >15 g dl(-1). The mean weekly dosage was 335 and 612 IU kg(-1), respectively, in the two active treatment groups. Significantly fewer (P < 0.05) epoetin alpha-treated patients experienced anaemia (Hb < 10 g dl(-1)) during the course of chemotherapy (300 IU kg(-1), 39%; 150 IU kg(-1), 48%; untreated, 66%). This was reflected in the significantly lower number of treated patients transfused [300 IU kg(-1), 20% (P< 0.001); 150 IU kg(-1), 45% (P< 0.05); untreated, 59%]. Epoetin alpha was well-tolerated, and there was no evidence of sustained, clinically significant, hypertension. In summary, epoetin alpha is effective and well-tolerated in maintaining Hb level and reducing transfusion requirement in patients undergoing cyclic chemotherapy for SCLC.
CitationEpoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. 1999, 80 (3-4):396-402 Br. J. Cancer
JournalBritish Journal of Cancer
- A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
- Authors: Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F
- Issue date: 2004 Oct
- Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
- Authors: Biesma B, van de Werf PR, Melissant CF, Brok RG
- Issue date: 2007 Oct
- Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
- Authors: Granetto C, Ricci S, Martoni A, Pezzella G, Testore F, Mattioli R, Lampignano M, Tacconi F, Porrozzi S, Gasparini G, Mantovani G, EPO-ITA3 Study Group.
- Issue date: 2003 Sep-Oct
- Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
- Authors: Welch RS, James RD, Wilkinson PM, Belli F, Cowan RA
- Issue date: 1995 Nov-Dec
- Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
- Authors: Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L
- Issue date: 2004